JAC Advance Access originally published online on December 4, 2006
Journal of Antimicrobial Chemotherapy 2007 59(6):1247-1260; doi:10.1093/jac/dkl460
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special section: Efflux |
Bacterial efflux pump inhibitors from natural sources
1 Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, University of London 29-39 Brunswick Square, London WC1N 1AX, UK 2 Antimicrobial Agents Research Group, Division of Immunity and Infection, The Medical School, University of Birmingham Birmingham B15 2TT, UK
*Corresponding author. Tel: +44-207-7535913; Fax: +44-207-7535909; E-mail: simon.gibbons{at}pharmacy.ac.uk
The rapid spread of bacteria expressing multidrug resistance (MDR) has necessitated the discovery of new antibacterials and resistance-modifying agents. Since the initial discovery of bacterial efflux pumps in the 1980s, many have been characterized in community- and hospital-acquired Gram-positive and Gram-negative pathogens, such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and, more recently, in mycobacteria. Efflux pumps are able to extrude structurally diverse compounds, including antibiotics used in a clinical setting; the latter are rendered therapeutically ineffective. Antibiotic resistance can develop rapidly through changes in the expression of efflux pumps, including changes to some antibiotics considered to be drugs of last resort. It is therefore imperative that new antibiotics, resistance-modifying agents and, more specifically, efflux pump inhibitors (EPIs) are characterized. The use of bacterial resistance modifiers such as EPIs could facilitate the re-introduction of therapeutically ineffective antibiotics back into clinical use such as ciprofloxacin and might even suppress the emergence of MDR strains. Here we review the literature on bacterial EPIs derived from natural sources, primarily those from plants. The resistance-modifying activities of many new chemical classes of EPIs warrant further studies to assess their potential as leads for clinical development.
Keywords: MDR , MRSA , Staphylococcus aureus , NorA, efflux , Mycobacterium , Pseudomonas , Escherichia , modulators
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Chusri, I. Villanueva, S. P. Voravuthikunchai, and J. Davies Enhancing antibiotic activity: a strategy to control Acinetobacter infections J. Antimicrob. Chemother., December 1, 2009; 64(6): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Lorenzi, A. Muselli, A. F. Bernardini, L. Berti, J.-M. Pages, L. Amaral, and J.-M. Bolla Geraniol Restores Antibiotic Activities against Multidrug-Resistant Isolates from Gram-Negative Species Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2209 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Woodford, D. W. Wareham, and on behalf of the UK Antibacterial Antisense Study Tackling antibiotic resistance: a dose of common antisense? J. Antimicrob. Chemother., February 1, 2009; 63(2): 225 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Lechner, S. Gibbons, and F. Bucar Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis J. Antimicrob. Chemother., August 1, 2008; 62(2): 345 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kumar, I. A. Khan, S. Koul, J. L. Koul, S. C. Taneja, I. Ali, F. Ali, S. Sharma, Z. M. Mirza, M. Kumar, et al. Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus J. Antimicrob. Chemother., June 1, 2008; 61(6): 1270 - 1276. [Abstract] [Full Text] [PDF]
|
|